1-Azabicyclo[3.3.1]nonane-5-carboxylic acid | 119103-11-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Azabicyclo[3.3.1]nonane-5-carboxylic acid
• CAS: 119103-11-6
• 化学式: C₉H₁₅NO₂
• 分子量: 169.22
• InChiKey: PVPLABKMWLPCSG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Bridgehead substituted azabicyclic derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0287356B1

  公开（公告）日：1996-01-24
• AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0934316A1

  公开（公告）日：1999-08-11
• US6121281A
  申请人：——

  公开号：US6121281A

  公开（公告）日：2000-09-19
• [EN] AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE<br/>[FR] DERIVES DE LA MUTILINE CARBAMOYLOXY AZABICYCLIQUE A USAGE ANTIBACTERIEN
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1998005659A1

  公开（公告）日：1998-02-12

  (EN) Compounds of formula (3), and pharmaceutically acceptable salts and derivatives thereof, in which R1 is vinyl or ethyl; and R2 is a group R3, R4CH2-, or R5R6C=CH-; wherein each of R3 and R4 is an azabicyclic ring system or R5 and R6 together with the carbon atom to which they are attached form an azabicyclic ring system, are useful in the prevention and treatment of microbial infections.(FR) Composés de la formule (3) et sels pharmaceutiquement acceptables et leurs dérivés dans laquelle : R1 représente vinyle ou éthyle; et R2 représente un groupe R3, R4CH2, ou R5R6C=CH-; dans lequel chacun des symboles R3 et R4 représente un système à noyau azabicycle, ou R5 et R6 forment ensemble avec l'atome de carbone auquel ils sont liés un système à noyau azabicycle. Lesdits composés servent dans la prévention et le traitement de certaines infections microbiennes.
• [EN] NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)<br/>[FR] NOUVEAUX INHIBITEURS DE LA POLY(ADP-RIBOSE)POLYMÉRASE (PARP)
  申请人：LEAD THERAPEUTICS INC

  公开号：WO2009029375A1

  公开（公告）日：2009-03-05

  A compound having the structure set forth in Formula (I): wherein the variables Y, R1, R2, R3, R4 and R5 are as defined herein. Compounds described herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of such compounds and pharmaceutical compositions to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.